Market Overview:
The global Pseudomonas Aeruginosa pneumonia drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of Pseudomonas Aeruginosa pneumonia, rising demand for novel drugs, and growing focus on research and development (R&D) activities. Based on type, the global Pseudomonas Aeruginosa pneumonia drug market is segmented into aerucin, EV-035, MEDI-3902, panobacumab and others. The aerucin segment is expected to account for the largest share of the global Pseudomonas Aeruginosa pneumonia drug market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Based on application, the global Pseudomonas Aeruginosapneumonia drug market is divided into hospital care settings, clinic care settings and others segments.
Product Definition:
Pseudomonas Aeruginosa Pneumonia Drug is a type of drug that is used to treat Pseudomonas Aeruginosa pneumonia. Pseudomonas Aeruginosa pneumonia is a serious infection that can occur in people who have weakened immune systems, such as those with cancer or HIV/AIDS. This drug helps to improve the patient's breathing and overall health.
Aerucin:
Aerucin is a drug that belongs to the class of drugs known as mucin-based or MIBs. It is used in the treatment of ventilator-associated pneumonia (VAP) and chronic obstructive pulmonary disease (COPD). Aerucin works by thickening the mucus in the lungs, making it difficult for bacteria to grow. The drug has been approved by both U.S.
EV-035:
It is a drug that helps in fighting against bacterial infection. It belongs to the class of drugs called as antibiotics. Antibiotics are used for the treatment and prevention of several bacterial infections, including pneumonia (inflammation of lungs).
Pseudomonas aeruginosa is a gram-positive bacteria that can cause respiratory infections and hospitalizations in patients with weak immune responses.
Application Insights:
Based on application, the global market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to increasing cases of bacterial and viral pneumonia across the globe. Bacterial pneumonia accounted for a larger share due to rising prevalence of HIV-infection, which increases susceptibility to pneumococcal infection. According to WHO, globally around 10 million people are living with HIV-AIDS and about 1 million die due to it every year; however, there is still a lot that remains unknown regarding this disease which boosts demand for effective treatment options such as AERUGINOSA drugs.
The clinic segment is expected register significant growth over the forecast period owing to growing awareness regarding better management practices for Pneumonia among patients along with an increase in visits for respiratory infections including colds & flu viruses among children & adults respectively.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its growth. In addition, rising incidence of HAI is also expected to drive regional growth over the forecast period. For instance, according to a study published in January 2018 issue of Clinical Infectious Diseases journal that analyzed data from COVID-19 outbreak between 2016 and 2017 it was observed that there were 1.4 million reported cases during this pandemic period which is about 10 times more than previous year (2016).
Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period owing to growing target population base coupled with rapidly improving healthcare infrastructure especially in developing countries such as India and China.
Growth Factors:
- Increasing incidence of Pseudomonas Aeruginosa Pneumonia
- Rising demand for better and more effective drugs to treat Pseudomonas Aeruginosa Pneumonia
- Growing number of clinical trials for new drugs to treat Pseudomonas Aeruginosa Pneumonia
- Increasing awareness about Pseudomonas Aeruginosa Pneumonia and its treatment options among patients and healthcare professionals
- Availability of government funding for research on new drugs to treat Pseudomonas Aeruginosa
Scope Of The Report
Report Attributes
Report Details
Report Title
Pseudomonas Aeruginosa Pneumonia Drug Market Research Report
By Type
Aerucin, EV-035, MEDI-3902, Panobacumab, Others
By Application
Hospital, Clinic, Others
By Companies
Aridis Pharmaceuticals LLC, Emergent BioSolutions Inc, MedImmune LLC, Polyphor Ltd, Aridis Pharmaceuticals LLC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
191
Number of Tables & Figures
134
Customization Available
Yes, the report can be customized as per your need.
Global Pseudomonas Aeruginosa Pneumonia Drug Market Report Segments:
The global Pseudomonas Aeruginosa Pneumonia Drug market is segmented on the basis of:
Types
Aerucin, EV-035, MEDI-3902, Panobacumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aridis Pharmaceuticals LLC
- Emergent BioSolutions Inc
- MedImmune LLC
- Polyphor Ltd
- Aridis Pharmaceuticals LLC
Highlights of The Pseudomonas Aeruginosa Pneumonia Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aerucin
- EV-035
- MEDI-3902
- Panobacumab
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pseudomonas Aeruginosa Pneumonia Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pseudomonas Aeruginosa Pneumonia Drug is an antibiotic used to treat pneumonia caused by the bacterium Pseudomonas aeruginosa.
Some of the major players in the pseudomonas aeruginosa pneumonia drug market are Aridis Pharmaceuticals LLC, Emergent BioSolutions Inc, MedImmune LLC, Polyphor Ltd, Aridis Pharmaceuticals LLC.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pseudomonas Aeruginosa Pneumonia Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pseudomonas Aeruginosa Pneumonia Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pseudomonas Aeruginosa Pneumonia Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pseudomonas Aeruginosa Pneumonia Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pseudomonas Aeruginosa Pneumonia Drug Market Size & Forecast, 2020-2028
4.5.1 Pseudomonas Aeruginosa Pneumonia Drug Market Size and Y-o-Y Growth
4.5.2 Pseudomonas Aeruginosa Pneumonia Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Aerucin
5.2.2 EV-035
5.2.3 MEDI-3902
5.2.4 Panobacumab
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pseudomonas Aeruginosa Pneumonia Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pseudomonas Aeruginosa Pneumonia Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Aerucin
9.6.2 EV-035
9.6.3 MEDI-3902
9.6.4 Panobacumab
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Aerucin
10.6.2 EV-035
10.6.3 MEDI-3902
10.6.4 Panobacumab
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Aerucin
11.6.2 EV-035
11.6.3 MEDI-3902
11.6.4 Panobacumab
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Aerucin
12.6.2 EV-035
12.6.3 MEDI-3902
12.6.4 Panobacumab
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Aerucin
13.6.2 EV-035
13.6.3 MEDI-3902
13.6.4 Panobacumab
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pseudomonas Aeruginosa Pneumonia Drug Market: Competitive Dashboard
14.2 Global Pseudomonas Aeruginosa Pneumonia Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aridis Pharmaceuticals LLC
14.3.2 Emergent BioSolutions Inc
14.3.3 MedImmune LLC
14.3.4 Polyphor Ltd
14.3.5 Aridis Pharmaceuticals LLC
